Combination of topotecan and cisplatin in relapsed patients with small cell lung cancer: a phase II study of the hellenic cooperative oncology group (HeCOG) (Journal article)

Christodoulou, C./ Kalofonos, H. P./ Briasoulis, E./ Bafaloukos, D./ Makatsoris, T./ Koutras, A./ Skarlos, D. V./ Samantas, E.

Full metadata record
DC FieldValueLanguage
dc.contributor.authorChristodoulou, C.en
dc.contributor.authorKalofonos, H. P.en
dc.contributor.authorBriasoulis, E.en
dc.contributor.authorBafaloukos, D.en
dc.contributor.authorMakatsoris, T.en
dc.contributor.authorKoutras, A.en
dc.contributor.authorSkarlos, D. V.en
dc.contributor.authorSamantas, E.en
dc.rightsDefault Licence-
dc.subjectAntineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic useen
dc.subjectCarcinoma, Small Cell/*drug therapyen
dc.subjectCisplatin/administration & dosageen
dc.subjectDrug Administration Scheduleen
dc.subjectInfusions, Intravenousen
dc.subjectLung Neoplasms/*drug therapyen
dc.subjectMiddle Ageden
dc.subjectSurvival Analysisen
dc.subjectTopotecan/administration & dosageen
dc.subjectTreatment Outcomeen
dc.titleCombination of topotecan and cisplatin in relapsed patients with small cell lung cancer: a phase II study of the hellenic cooperative oncology group (HeCOG)en
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.abstractPURPOSE: To assess the safety and efficacy of a 3-day schedule of cisplatin and topotecan in patients with recurrent small-cell lung cancer (SCLC). METHODS: Thirty-four relapsed patients were treated with cisplatin 20 mg/m2 and topotecan 0.9 mg/m2, both given on days 1-3 every 3 weeks, in a phase II study. RESULTS: Complete response (CR) was achieved in two patients (6%), partial response (PR) in 4 (12%), stable disease in 6 (18%) and progressive disease in 14 (41%). Eight patients (23%) were non-evaluable for response. Among 21 sensitive patients, 2 (9.5%) achieved CR and 3 (14%) PR. Among 13 refractory patients, none achieved CR and only 1 (8%) PR. Median survival was 6.5 months for all patients, 7.8 for sensitive and 6.2 for refractory. Median time to progression (TTP) was 4.4 months for all patients, 5.9 for sensitive and 3.2 for refractory. Grade 3-4 toxicities included anemia (15%), thrombocytopenia (15%), neutropenia (42%), nausea/vomiting (3%), and alopecia (6%). No toxic death occurred. CONCLUSIONS: This 3-day schedule was well tolerated, produced modest response rates but good survival and TTP both in sensitive and refractory patients with relapsed SCLC.en
heal.journalNameCancer Chemother Pharmacolen
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
File Description SizeFormat 
Christodoulou-2006-Combination of topot.pdf201.2 kBAdobe PDFView/Open    Request a copy

 Please use this identifier to cite or link to this item:
  This item is a favorite for 0 people.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.